Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Nanobiotix (NBTX – Research Report) yesterday and set a price target of $9.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonathan Chang has given his Buy rating due to a combination of factors, including Nanobiotix’s recent operational advancements and strategic collaborations. The initiation of the Phase II CONVERGE study for NBTXR3 in partnership with JNJ, along with the extension of the JNJ licensing agreement, provides a solid foundation for future growth. The company’s presentations at major conferences further highlight the potential of their novel radioenhancer, NBTXR3, in treating unresectable Stage III non-small cell lung cancer.
Additionally, Nanobiotix’s financial position, with a cash balance that extends its runway into mid-2026, supports its ongoing research and development efforts. Upcoming milestones, such as data updates from collaborations and the advancement of various clinical studies, are expected to further validate NBTXR3’s efficacy and commercial potential. These elements collectively underpin Chang’s optimistic outlook on the stock.